Daniel R Kuritzkes

Author PubWeight™ 259.81‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science 2010 9.61
2 Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One 2009 8.37
3 Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med 2004 6.87
4 Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 2003 5.79
5 Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Infect Dis 2008 5.20
6 Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. Clin Infect Dis 2008 5.14
7 Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clin Infect Dis 2003 4.51
8 HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance. AIDS 2007 3.94
9 Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211. J Infect Dis 2007 3.75
10 Update of the drug resistance mutations in HIV-1: Spring 2008. Top HIV Med 2008 3.66
11 Update of the drug resistance mutations in HIV-1: December 2009. Top HIV Med 2009 3.52
12 Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial. Ann Intern Med 2014 3.48
13 Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study. Clin Infect Dis 2005 3.47
14 Quantitative deep sequencing reveals dynamic HIV-1 escape and large population shifts during CCR5 antagonist therapy in vivo. PLoS One 2009 3.40
15 Antiretroviral-free HIV-1 remission and viral rebound after allogeneic stem cell transplantation: report of 2 cases. Ann Intern Med 2014 3.24
16 Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial. JAMA 2006 3.23
17 Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis. JAMA 2011 3.08
18 Update of the drug resistance mutations in HIV-1: Fall 2006. Top HIV Med 2006 3.06
19 HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211. Clin Infect Dis 2007 3.05
20 Update of the Drug Resistance Mutations in HIV-1. Top HIV Med 2008 2.91
21 Update of the drug resistance mutations in HIV-1: December 2010. Top HIV Med 2010 2.91
22 Update of the drug resistance mutations in HIV-1: 2007. Top HIV Med 2007 2.79
23 Blinded, multicenter comparison of methods to detect a drug-resistant mutant of human immunodeficiency virus type 1 at low frequency. J Clin Microbiol 2006 2.45
24 Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure. J Infect Dis 2010 2.45
25 Accuracy of the TRUGENE HIV-1 genotyping kit. J Clin Microbiol 2003 2.32
26 Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262). AIDS 2011 2.22
27 Long-term reduction in peripheral blood HIV type 1 reservoirs following reduced-intensity conditioning allogeneic stem cell transplantation. J Infect Dis 2013 2.17
28 Consequences and determinants of adherence to antiretroviral medication: results from Adult AIDS Clinical Trials Group protocol 370. Antivir Ther 2002 2.07
29 Xenotropic murine leukemia virus-related virus prevalence in patients with chronic fatigue syndrome or chronic immunomodulatory conditions. J Infect Dis 2010 2.05
30 Update of the drug resistance mutations in HIV-1: Fall 2005. Top HIV Med 2005 2.04
31 Limited immune restoration after 3 years' suppression of HIV-1 replication in patients with moderately advanced disease. AIDS 2002 2.02
32 Relative replicative fitness of human immunodeficiency virus type 1 mutants resistant to enfuvirtide (T-20). J Virol 2004 1.91
33 Higher-than-expected rates of lactic acidosis among highly active antiretroviral therapy-treated women in Botswana: preliminary results from a large randomized clinical trial. J Acquir Immune Defic Syndr 2007 1.90
34 Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials. J Acquir Immune Defic Syndr 2005 1.87
35 In vivo emergence of vicriviroc resistance in a human immunodeficiency virus type 1 subtype C-infected subject. J Virol 2008 1.84
36 Update of the Drug Resistance Mutations in HIV-1: 2005. Top HIV Med 2005 1.83
37 In vivo evidence for instability of episomal human immunodeficiency virus type 1 cDNA. J Virol 2005 1.80
38 Challenges in clinical trial design for HIV-1 cure research. Lancet 2013 1.74
39 Outcomes after virologic failure of first-line ART in South Africa. AIDS 2010 1.74
40 Drug resistance mutations in HIV-1. Top HIV Med 2003 1.72
41 Instantaneous inhibitory potential is similar to inhibitory quotient at predicting HIV-1 response to antiretroviral therapy. Clin Infect Dis 2010 1.72
42 Low-level detection and quantitation of cellular HIV-1 DNA and 2-LTR circles using droplet digital PCR. J Virol Methods 2012 1.65
43 Racial differences in virologic failure associated with adherence and quality of life on efavirenz-containing regimens for initial HIV therapy: results of ACTG A5095. J Acquir Immune Defic Syndr 2007 1.64
44 Interruption of enfuvirtide in HIV-1 infected adults with incomplete viral suppression on an enfuvirtide-based regimen. J Infect Dis 2006 1.62
45 Update of the drug resistance mutations in HIV-1: 2004. Top HIV Med 2004 1.62
46 Response to vicriviroc in treatment-experienced subjects, as determined by an enhanced-sensitivity coreceptor tropism assay: reanalysis of AIDS clinical trials group A5211. J Infect Dis 2009 1.61
47 High rate of K65R for antiretroviral therapy-naive patients with subtype C HIV infection failing a tenofovir-containing first-line regimen. AIDS 2012 1.60
48 Substitution of nevirapine because of efavirenz toxicity in AIDS clinical trials group A5095. Clin Infect Dis 2010 1.53
49 Modeling long-term HIV dynamics and antiretroviral response: effects of drug potency, pharmacokinetics, adherence, and drug resistance. J Acquir Immune Defic Syndr 2005 1.52
50 Relationship between minority nonnucleoside reverse transcriptase inhibitor resistance mutations, adherence, and the risk of virologic failure. AIDS 2012 1.52
51 Rapid emergence of enfuvirtide resistance in HIV-1-infected patients: results of a clonal analysis. J Acquir Immune Defic Syndr 2006 1.49
52 Comparison of two indinavir/ritonavir regimens in the treatment of HIV-infected individuals. J Acquir Immune Defic Syndr 2004 1.48
53 Antiviral activity of lamivudine in salvage therapy for multidrug-resistant HIV-1 infection. Clin Infect Dis 2005 1.47
54 Antiretroviral drug resistance in HIV-1-infected patients experiencing persistent low-level viremia during first-line therapy. J Infect Dis 2011 1.45
55 In vivo fitness cost of the M184V mutation in multidrug-resistant human immunodeficiency virus type 1 in the absence of lamivudine. J Virol 2008 1.45
56 Systematic evaluation of allele-specific real-time PCR for the detection of minor HIV-1 variants with pol and env resistance mutations. J Virol Methods 2007 1.43
57 A multi-investigator/institutional DNA bank for AIDS-related human genetic studies: AACTG Protocol A5128. HIV Clin Trials 2003 1.42
58 A pièce de resistance: how HIV-1 escapes small molecule CCR5 inhibitors. Curr Opin HIV AIDS 2009 1.41
59 Safety, pharmacokinetics, and antiretroviral activity of multiple doses of ibalizumab (formerly TNX-355), an anti-CD4 monoclonal antibody, in human immunodeficiency virus type 1-infected adults. Antimicrob Agents Chemother 2008 1.39
60 Drug resistance mutations in HIV-1. Top HIV Med 2004 1.37
61 Episomal viral cDNAs identify a reservoir that fuels viral rebound after treatment interruption and that contributes to treatment failure. PLoS Pathog 2011 1.32
62 Enumeration of CD4+ T-cells using a portable microchip count platform in Tanzanian HIV-infected patients. PLoS One 2011 1.32
63 Fitness comparison of thymidine analog resistance pathways in human immunodeficiency virus type 1. J Virol 2006 1.32
64 Virologic failure of protease inhibitor-based second-line antiretroviral therapy without resistance in a large HIV treatment program in South Africa. PLoS One 2012 1.31
65 Effect of raltegravir resistance mutations in HIV-1 integrase on viral fitness. J Acquir Immune Defic Syndr 2010 1.30
66 Quantum dot-based HIV capture and imaging in a microfluidic channel. Biosens Bioelectron 2009 1.27
67 Three distinct phases of HIV-1 RNA decay in treatment-naive patients receiving raltegravir-based antiretroviral therapy: ACTG A5248. J Infect Dis 2013 1.26
68 Rapid automated cell quantification on HIV microfluidic devices. Lab Chip 2009 1.25
69 Less than the sum of its parts: failure of a tenofovir-abacavir-Lamivudine triple-nucleoside regimen. J Infect Dis 2005 1.25
70 The size of the expressed HIV reservoir predicts timing of viral rebound after treatment interruption. AIDS 2016 1.25
71 Chemokine antagonists as therapeutics: focus on HIV-1. Annu Rev Med 2007 1.24
72 AIDS clinical trials group 5197: a placebo-controlled trial of immunization of HIV-1-infected persons with a replication-deficient adenovirus type 5 vaccine expressing the HIV-1 core protein. J Infect Dis 2010 1.24
73 Metabolic effects of protease inhibitor-sparing antiretroviral regimens given as initial treatment of HIV-1 Infection (AIDS Clinical Trials Group Study A5095). J Acquir Immune Defic Syndr 2007 1.20
74 Interaction of reverse transcriptase (RT) mutations conferring resistance to lamivudine and etravirine: effects on fitness and RT activity of human immunodeficiency virus type 1. J Virol 2011 1.19
75 The L74V mutation in human immunodeficiency virus type 1 reverse transcriptase counteracts enhanced excision of zidovudine monophosphate associated with thymidine analog resistance mutations. Antimicrob Agents Chemother 2005 1.18
76 Efficient on-chip isolation of HIV subtypes. Lab Chip 2012 1.17
77 A randomized study of antiviral medication switch at lower- versus higher-switch thresholds: AIDS Clinical Trials Group Study A5115. Antivir Ther 2007 1.17
78 Monitoring HIV treatment in developing countries. BMJ 2006 1.13
79 Prevalence and significance of HIV-1 drug resistance mutations among patients on antiretroviral therapy with detectable low-level viremia. Antimicrob Agents Chemother 2012 1.13
80 The impact of the President's Emergency Plan for AIDS Relief (PEPfAR) beyond HIV and why it remains essential. Clin Infect Dis 2010 1.12
81 Increased risk of virologic rebound in patients on antiviral therapy with a detectable HIV load <48 copies/mL. PLoS One 2012 1.10
82 Clinical implications of HIV-1 minority variants. Clin Infect Dis 2013 1.09
83 Acute on-chip HIV detection through label-free electrical sensing of viral nano-lysate. Small 2013 1.07
84 Antiretroviral therapy-associated toxicities in the resource-poor world: the challenge of a limited formulary. J Infect Dis 2007 1.07
85 HIV-1 entry inhibitors: recent development and clinical use. Curr Opin Virol 2013 1.07
86 Nanoplasmonic quantitative detection of intact viruses from unprocessed whole blood. ACS Nano 2013 1.07
87 The design and validation of a novel phenotypic assay to determine HIV-1 coreceptor usage of clinical isolates. J Virol Methods 2010 1.06
88 Emerging integrase inhibitor resistance mutations in raltegravir-treated HIV-1-infected patients with low-level viremia. AIDS 2011 1.05
89 Emerging nanotechnology approaches for HIV/AIDS treatment and prevention. Nanomedicine (Lond) 2010 1.05
90 HIV-1-infected antiretroviral-treated patients with prolonged partial viral suppression: clinical, virologic, and immunologic course. J Acquir Immune Defic Syndr 2003 1.05
91 Pharmacodynamics of antiretroviral agents in HIV-1 infected patients: using viral dynamic models that incorporate drug susceptibility and adherence. J Pharmacokinet Pharmacodyn 2006 1.05
92 Emerging technologies for point-of-care management of HIV infection. Annu Rev Med 2014 1.05
93 Three-year safety and efficacy of vicriviroc, a CCR5 antagonist, in HIV-1-infected treatment-experienced patients. J Acquir Immune Defic Syndr 2010 1.04
94 Design issues in initial HIV-treatment trials: focus on ACTG A5095. Antivir Ther 2006 1.04
95 Change in high-sensitivity c-reactive protein levels following initiation of efavirenz-based antiretroviral regimens in HIV-infected individuals. AIDS Res Hum Retroviruses 2010 1.04
96 Tropism testing in the clinical management of HIV-1 infection. Curr Opin HIV AIDS 2009 1.03
97 Continued evolution in gp41 after interruption of enfuvirtide in subjects with advanced HIV type 1 disease. AIDS Res Hum Retroviruses 2006 0.99
98 Impact of minority nonnucleoside reverse transcriptase inhibitor resistance mutations on resistance genotype after virologic failure. J Infect Dis 2012 0.97
99 Simple filter microchip for rapid separation of plasma and viruses from whole blood. Int J Nanomedicine 2012 0.97
100 Lymphoma diagnosis and plasma Epstein-Barr virus load during vicriviroc therapy: results of the AIDS Clinical Trials Group A5211. Clin Infect Dis 2009 0.96
101 Evolution of CCR5 antagonist resistance in an HIV-1 subtype C clinical isolate. J Acquir Immune Defic Syndr 2010 0.96
102 Efavirenz-based regimens in treatment-naive patients with a range of pretreatment HIV-1 RNA levels and CD4 cell counts. J Infect Dis 2008 0.96
103 Resistance in pediatric patients experiencing virologic failure with first-line and second-line antiretroviral therapy. Pediatr Infect Dis J 2013 0.96
104 Relationship of HIV reservoir characteristics with immune status and viral rebound kinetics in an HIV therapeutic vaccine study. AIDS 2014 0.94
105 HIV-1 clinical isolates resistant to CCR5 antagonists exhibit delayed entry kinetics that are corrected in the presence of drug. J Virol 2011 0.94
106 Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Top HIV Med 2009 0.93
107 Env sequence determinants in CXCR4-using human immunodeficiency virus type-1 subtype C. Virology 2012 0.93
108 Baseline CD4(+) T-cell counts and weighted background susceptibility scores strongly predict response to maraviroc regimens in treatment-experienced patients. Antivir Ther 2011 0.92
109 Viral dynamics and in vivo fitness of HIV-1 in the presence and absence of enfuvirtide. J Acquir Immune Defic Syndr 2008 0.92
110 HIV-1 subtype as a determinant of disease progression. J Infect Dis 2008 0.92
111 Postpartum antiretroviral drug resistance in HIV-1-infected women receiving pregnancy-limited antiretroviral therapy. AIDS 2010 0.92
112 Factors associated with viral rebound in HIV-1-infected individuals enrolled in a therapeutic HIV-1 gag vaccine trial. J Infect Dis 2011 0.91
113 Intracellular nucleoside triphosphate concentrations in HIV-infected patients on dual nucleoside reverse transcriptase inhibitor therapy. Antivir Ther 2007 0.91
114 Drug resistance and viral tropism in HIV-1 subtype C-infected patients in KwaZulu-Natal, South Africa: implications for future treatment options. J Acquir Immune Defic Syndr 2011 0.91
115 Assessing resistance costs of antiretroviral therapies via measures of future drug options. J Infect Dis 2003 0.90
116 Delaying a treatment switch in antiretroviral-treated HIV type 1-infected patients with detectable drug-resistant viremia does not have a profound effect on immune parameters: AIDS Clinical Trials Group Study A5115. AIDS Res Hum Retroviruses 2009 0.90
117 TORO: ninety-six-week virologic and immunologic response and safety evaluation of enfuvirtide with an optimized background of antiretrovirals. AIDS Patient Care STDS 2007 0.90
118 Early warning indicators for first-line virologic failure independent of adherence measures in a South African urban clinic. AIDS Patient Care STDS 2013 0.90
119 Persistent antiretroviral activity of nucleoside analogues after prolonged zidovudine and lamivudine therapy as demonstrated by rapid loss of activity after discontinuation. J Acquir Immune Defic Syndr 2004 0.89
120 Role of Baseline pol Genotype in HIV-1 Fitness Evolution. J Acquir Immune Defic Syndr 2003 0.89
121 Associations of T cell activation and inflammatory biomarkers with virological response to darunavir/ritonavir plus raltegravir therapy. J Antimicrob Chemother 2013 0.88
122 Treatment-mediated alterations in HIV fitness preserve CD4+ T cell counts but have minimal effects on viral load. PLoS Comput Biol 2010 0.88
123 SHIV-162P3 infection of rhesus macaques given maraviroc gel vaginally does not involve resistant viruses. PLoS One 2011 0.87
124 Phenotypic and genotypic analysis of biologically cloned human immunodeficiency virus type 1 isolates from patients treated with zidovudine and lamivudine. Antimicrob Agents Chemother 2002 0.87
125 Assessing human immunodeficiency virus type 1 tropism: Comparison of assays using replication-competent virus versus plasma-derived pseudotyped virions. J Clin Microbiol 2009 0.85
126 Challenges for the clinical development of new nucleoside reverse transcriptase inhibitors for HIV infection. Antivir Ther 2005 0.85
127 Viremic control and viral coreceptor usage in two HIV-1-infected persons homozygous for CCR5 Δ32. AIDS 2015 0.85
128 Enfuvirtide cerebrospinal fluid (CSF) pharmacokinetics and potential use in defining CSF HIV-1 origin. Antivir Ther 2008 0.85
129 Intensification of a triple-nucleoside regimen with tenofovir or efavirenz in HIV-1-infected patients with virological suppression. AIDS 2007 0.84
130 Amdoxovir versus placebo with enfuvirtide plus optimized background therapy for HIV-1-infected subjects failing current therapy (AACTG A5118). Antivir Ther 2006 0.84
131 Pharmacogenomics of HIV therapy: summary of a workshop sponsored by the National Institute of Allergy and Infectious Diseases. HIV Clin Trials 2011 0.84
132 High prevalence of primary lamivudine and nelfinavir resistance in HIV-1-infected pregnant women in the United States, 1998-2004. AIDS 2007 0.83
133 Prevalence and clinical associations of CXCR4-using HIV-1 among treatment-naive subtype C-infected women in Botswana. J Acquir Immune Defic Syndr 2011 0.83
134 Early HIV RNA decay during raltegravir-containing regimens exhibits two distinct subphases (1a and 1b). AIDS 2015 0.82
135 A comparison of three initial antiretroviral AIDS regimens. N Engl J Med 2007 0.82
136 Virologic response, early HIV-1 decay, and maraviroc pharmacokinetics with the nucleos(t)ide-free regimen of maraviroc plus darunavir/ritonavir in a pilot study. J Acquir Immune Defic Syndr 2013 0.82
137 Accuracy, precision, and consistency of expert HIV type 1 genotype interpretation: an international comparison (The GUESS Study). Clin Infect Dis 2005 0.82
138 Total energy expenditure and carbohydrate oxidation are increased in the human immunodeficiency virus lipodystrophy syndrome. Metabolism 2003 0.82
139 Effect of the Q207D mutation in HIV type 1 reverse transcriptase on zidovudine susceptibility and replicative fitness. J Acquir Immune Defic Syndr 2005 0.82
140 Treatment options after virological failure of first-line tenofovir-based regimens in South Africa: an analysis by deep sequencing. AIDS 2016 0.82
141 Hematopoietic stem cell transplantation for HIV cure. J Clin Invest 2016 0.81
142 Coadministration of lopinavir/ritonavir and rifampicin in HIV and tuberculosis co-infected adults in South Africa. PLoS One 2012 0.81
143 Virologic characterization of HIV type 1 with a codon 70 deletion in reverse transcriptase. J Acquir Immune Defic Syndr 2007 0.81
144 Brief Report: Relationship Among Viral Load Outcomes in HIV Treatment Interruption Trials. J Acquir Immune Defic Syndr 2016 0.80
145 Report from the XV International HIV Drug Resistance Workshop. AIDS Clin Care 2006 0.79
146 Development of a didanosine genotypic resistance interpretation system based on large derivation and validation datasets. AIDS 2010 0.79
147 Interleukin-2: trials and tribulations. J Infect Dis 2009 0.79
148 Clonal CD8+ T cell expansions in peripheral blood from human immunodeficiency virus type 1-infected children. J Infect Dis 2002 0.79
149 Vicriviroc resistance decay and relative replicative fitness in HIV-1 clinical isolates under sequential drug selection pressures. J Virol 2012 0.79
150 Performance of human immunodeficiency virus type 1 gp41 assays for detecting enfuvirtide (T-20) resistance mutations. J Clin Microbiol 2006 0.78
151 Phylogenetic evidence of HIV-1 sequence evolution in subjects with persistent low-level viraemia. Antivir Ther 2014 0.78
152 Differential use of CCR5 by HIV-1 clinical isolates resistant to small-molecule CCR5 antagonists. Antimicrob Agents Chemother 2012 0.78
153 Two-way Bayesian hierarchical phylogenetic models: An application to the co-evolution of gp120 and gp41 during and after enfuvirtide treatment. Comput Stat Data Anal 2009 0.78
154 Characteristics and outcomes of initial virologic suppressors during analytic treatment interruption in a therapeutic HIV-1 gag vaccine trial. PLoS One 2012 0.78
155 Genotypic tests for determining coreceptor usage of HIV-1. J Infect Dis 2010 0.77
156 Evaluation of HIV-1 ambiguous nucleotide frequency during antiretroviral treatment interruption. J Acquir Immune Defic Syndr 2012 0.77
157 The future of HIV treatment. J Acquir Immune Defic Syndr 2012 0.77
158 An update on HIV-1 antiretroviral resistance. Curr Opin HIV AIDS 2006 0.76
159 Questions to and answers from the International AIDS Society-USA Resistance Testing Guidelines Panel. Top HIV Med 2003 0.76
160 Least among equals. Clin Infect Dis 2012 0.75
161 Monitoring processed, mature Human Immunodeficiency Virus type 1 particles immediately following treatment with a protease inhibitor-containing treatment regimen. AIDS Res Ther 2005 0.75
162 Prevention of HIV-1 transmission with postexposure prophylaxis after inadvertent infected blood transfusion. AIDS 2014 0.75
163 Development of dual-class antiretroviral drug resistance in a child coinfected with HIV and tuberculosis: a case report from KwaZulu-Natal, South Africa. J Trop Pediatr 2008 0.75
164 When more is less. Clin Infect Dis 2004 0.75
165 Report from the 2012 International Workshop on HIV & Hepatitis Virus Drug Resistance and Curative Strategies. J Watch AIDS Clin Care 2012 0.75
166 Report from the XVIII International HIV Drug Resistance Workshop. J Watch AIDS Clin Care 2009 0.75
167 Report from the XVI International HIV Drug Resistance Workshop. AIDS Clin Care 2007 0.75
168 Drug development strategies for salvage therapy: conflicts and solutions. AIDS Res Hum Retroviruses 2006 0.75
169 A plea for justice for jailed medical workers. Science 2006 0.75
170 Increased replication of HIV-1 minor variants during hematopoietic stem-cell mobilization with filgrastim. J Infect Dis 2004 0.75
171 Report from the XVII International HIV Drug Resistance Workshop. AIDS Clin Care 2008 0.75
172 An Abundance of Choices: Comment on "Choice of Initial Combination Antiretroviral Therapy in Individuals With HIV Infection: Determinants and Outcomes". Arch Intern Med 2012 0.75
173 Once-daily quadruple-drug therapy with adefovir dipivoxil, Lamivudine, Didanosine, and efavirenz in treatment-naive human immunodeficiency virus type 1-infected patients. J Infect Dis 2002 0.75
174 Correction: Real-Time Predictions of Reservoir Size and Rebound Time during Antiretroviral Therapy Interruption Trials for HIV. PLoS Pathog 2017 0.75
175 Correction: Coadministration of Lopinavir/Ritonavir and Rifampicin in HIV and Tuberculosis Co-Infected Adults in South Africa. PLoS One 2013 0.75